Concomitant therapy with mood stabilizers was permitted throughout the open-label extension and continuation studies.
Concomitant therapy with mood stabilizers and antidepressant medications was permitted throughout the open-label studies.
Concomitant therapy with mood stabilizers was permitted in both open-label studies and in 2 of the 3 acute double-blind studies.
Changes to stent design and composition and concomitant therapy have failed to improve stent patency; therefore, alternative techniques to safely prolong stent patency are required.
Concomitant therapy varied among the different trials [Table 3].
Additionally, the following individual patient information was recorded: age, gender, staging, pretreatment, and concomitant therapy.
In the study by Scheen 2006, concomitant therapy with metformin was used by 47 to 52%, sulphonylurea alone by 16%, and metformin plus sulphonylurea by 10 to 11%.
All patients received standard concomitant therapy.
Concomitant therapy was permitted throughout the study.
Concomitant therapy consists of a PPI (standard dose, b.i.d).
Concomitant therapy with immune suppressants, except steroids, is allowed.
